|
Purpose This test by studying bortezomib (bortezomib, Velcade ) in vitro in acute myeloid leukemia cell line SHI 1 cell proliferation and apoptosis and protein PI3K, Akt, P-Akt, caspase- 3 expression to explore its mechanism of acute myeloid leukemia . Methods Different concentrations of bortezomib (0,5,50,100,150 ng / ml) acting on the SHI 1 cell apoptosis by flow cytometry . Tetrazolium salt (MTT) Determination of cell proliferation , Western blotting determination PI3K, Akt, P-Akt, caspase-3 protein expression . Results 5-100 ng / mL bortezomib can effectively suppress SHI 1 cell proliferation and induce apoptosis , as the concentration increased and prolonged duration of action allows significantly increased apoptosis rate (P lt; 0 01 ) . Of which 50 ng / mL dose treatment SHI 1 cells 12 hours that is able to inhibit cell proliferation in a time- and dose- dependent manner (P lt; 0.01). Western blotting test showed that : with the increase of drug concentration , Akt expression was not significantly change , PI3K, P-Akt expression gradually decreased , 150 ng / mL bortezomib for 24h PI3K, P-Akt expression minimum ; caspase-3 activity gradually increased in a dose -dependent manner. Conclusion The proteasome inhibitor bortezomib inhibits SHI 1 cell proliferation and induced apoptosis was significantly reduced PI3K, P-Akt protein expression associated with elevated caspase-3 activity , suggesting that bortezomib induce SHI 1 apoptosis by inhibiting the PI3K/Akt pathway may be activated caspase-3 and execution of apoptosis achieved.
|